Life Sciences team advises Crescendo Biologics on $790 million collaboration with Takeda Pharmaceutical Company

Crescendo Biologics turned to Gowling WLG's Life Sciences team, led by partner Patrick Duxbury, for assistance on its collaboration with Takeda Pharmaceutical Company with the aim of discovering, developing and commercialising Humabody®-based therapeutics aimed at cancer indications with a high unmet medical need. 

Crescendo will use its patented transgenic platform and protein engineering expertise to develop Humabody® candidates against targets nominated by Takeda.

Under the term of the collaboration, Crescendo is entitled to receive up to $36 million via a series of milestones, funding, investment and upfront payment, while Takeda has the right to develop and commercialise selected Humabody®-based therapeutics arising from the partnership, triggering further payments of up $754 million.

The deal completed in October 2016.